Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, announces the closing of its acquisition of Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million.
Read the full article: Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-Based Fully Integrated Biopharmaceutical Company //
Source: https://www.globenewswire.com/news-release/2026/05/04/3286729/0/en/gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company.html?_gl=1*12eezkt*_up*MQ..*_ga*MTIyOTc5ODk3LjE3Nzc5MDAxMzE.*_ga_B6167QB2TF*czE3Nzc5MDAxMzAkbzEkZzAkdDE3Nzc5MDAxMzAkajYwJGwwJGg3MjU3NTk2NA..*_ga_ERWPGTJ5X8*czE3Nzc5MDAxMzAkbzEkZzAkdDE3Nzc5MDAxMzAkajYwJGwwJGgw